Sunesis Pharmaceuticals Added to Russell Microcap® Index
June 26 2017 - 7:00AM
Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced that it
was added to the Russell Microcap® Index when the Russell
Investment Group reconstituted its family of U.S. indexes effective
today, June 26, 2017.
Membership in the Russell Microcap Index, which
remains in place for one year, means automatic inclusion in the
appropriate growth and value style indexes. FTSE Russell determines
membership for its Russell indexes primarily by objective,
market-capitalization rankings and style attributes.
About Sunesis
Pharmaceuticals
Sunesis is a biopharmaceutical company focused
on the development and commercialization of new oncology
therapeutics for the potential treatment of solid and hematologic
cancers. Sunesis has built a highly-experienced cancer drug
development organization committed to improving the lives of people
with cancer. Currently, the company is focused on advancing its
novel kinase-inhibitor pipeline, which includes its proprietary
non-covalent BTK-inhibitor, SNS-062.
For additional information on Sunesis, please
visit http://www.sunesis.com.
SUNESIS and the logos are trademarks
of Sunesis Pharmaceuticals, Inc.
This press release contains forward-looking
statements, including statements related to the continued
development and commercialization of vosaroxin, the timing of our
Phase 1b/2 trial of SNS-062, and the sufficiency of Sunesis’ cash
and funding into June 2018. Words such as “advance,”
“continue,” “expect,” “will” and similar expressions are intended
to identify forward-looking statements. These forward-looking
statements are based upon Sunesis' current expectations.
Forward-looking statements involve risks and uncertainties.
Sunesis' actual results and the timing of events could differ
materially from those anticipated in such forward-looking
statements as a result of these risks and uncertainties, which
include, without limitation, the risk that Sunesis may not be able
to receive regulatory approval of vosaroxin in the U.S.
or Europe, that Sunesis' development activities for SNS-062 or
vosaroxin could be otherwise halted or significantly delayed for
various reasons, risks related to Sunesis' need for substantial
additional funding to complete the development and
commercialization of vosaroxin and other product candidates,
including SNS-062, the risk that Sunesis' clinical studies for
vosaroxin or other product candidates, including SNS-062 or its
pipeline of kinase inhibitors, may not demonstrate safety or
efficacy or lead to regulatory approval, the risk that data to date
and trends may not be predictive of future data or results, risks
related to the timing or conduct of Sunesis' clinical trials, and
risks related to Sunesis' ability to raise the capital that it
believes to be accessible and is required to fully finance the
development and commercialization of SNS-062, vosaroxin and other
product candidates. These and other risk factors are discussed
under "Risk Factors" and elsewhere in Sunesis' Quarterly Report on
Form 10-Q for the quarter ended March 31, 2017 and Sunesis'
other filings with the Securities and Exchange
Commission. Sunesis expressly disclaims any obligation or
undertaking to release publicly any updates or revisions to any
forward-looking statements contained herein to reflect any change
in Sunesis' expectations with regard thereto or any change in
events, conditions or circumstances on which any such statements
are based.
Investor and Media Inquiries:
Maeve Conneighton
Argot Partners
212-600-1902
Dan Swisher
Sunesis Pharmaceuticals Inc.
650-266-3715
Sunesis Pharmaceuticals (NASDAQ:SNSS)
Historical Stock Chart
From Jun 2024 to Jul 2024
Sunesis Pharmaceuticals (NASDAQ:SNSS)
Historical Stock Chart
From Jul 2023 to Jul 2024